<DOC>
	<DOCNO>NCT00005606</DOCNO>
	<brief_summary>RATIONALE : Peripheral blood lymphocyte therapy may effective treatment prevention Epstein-Barr virus infection follow transplantation . PURPOSE : Phase II trial study effectiveness peripheral blood lymphocyte therapy treat prevent lymphoproliferative disorder patient Epstein-Barr virus infection follow transplantation .</brief_summary>
	<brief_title>Peripheral Blood Lymphocyte Therapy Prevent Lymphoproliferative Disorders Caused Epstein-Barr Virus Patients Who Have Undergone Transplantation</brief_title>
	<detailed_description>OBJECTIVES : - Compare efficacy Epstein Barr virus ( EBV ) reactive autologous allogeneic lymphocyte clone ex vivo target EBV immortalized lymphoblast patient undergo solid organ transplant T cell deplete bone marrow transplant . - Determine efficacy regimens treatment prophylaxis patient develop EBV viremia EBV induce lymphoproliferative disease . OUTLINE : Autologous allogeneic Epstein Barr virus ( EBV ) reactive lymphocyte isolate patient sibling test vitro cytotoxic activity . Patients develop EBV viremia EBV relate lymphoproliferative disease transplant receive autologous Epstein Barr virus ( EBV ) reactive lymphocyte IV 20 minute . Patients receive allogeneic EBV reactive lymphocytes autologous lymphocyte fail control EBV proliferation sufficient autologous reactive lymphocyte isolate . Treatment repeat every 4 week presence EBV viremia lymphoproliferative disease . After 5 patient receive therapy without unacceptable toxicity , patient may receive lymphocyte prophylactic therapy . Patients follow 4 week , 8 week , 6 month , 12 month . PROJECTED ACCRUAL : A total 10-20 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Lymphoproliferative Disorders</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Patients receive receive solid organ transplant T cell deplete bone marrow transplant Epstein Barr virus ( EBV ) DNA detectable seronegative OR EBV seropositive Fully match one HLA antigen mismatch sibling donor HIV negative Hepatitis B surface antigen negative Hepatitis C antibody negative No old 65 year No prior primary malignancy within past 5 year donor except previously resect skin cancer PATIENT CHARACTERISTICS : Age : Not specify Performance status : Not specify Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Not specify Renal : Not specify PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy Not specify Endocrine therapy Not specify Radiotherapy Not specify Surgery Not specify</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>stage I adult Hodgkin lymphoma</keyword>
	<keyword>stage II adult Hodgkin lymphoma</keyword>
	<keyword>stage III adult Hodgkin lymphoma</keyword>
	<keyword>stage IV adult Hodgkin lymphoma</keyword>
	<keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>stage I cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage II cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage III cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage IV cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>isolated plasmacytoma bone</keyword>
	<keyword>extramedullary plasmacytoma</keyword>
	<keyword>stage 0 chronic lymphocytic leukemia</keyword>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
	<keyword>stage I chronic lymphocytic leukemia</keyword>
	<keyword>stage II chronic lymphocytic leukemia</keyword>
	<keyword>stage III chronic lymphocytic leukemia</keyword>
	<keyword>stage IV chronic lymphocytic leukemia</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>untreated adult acute lymphoblastic leukemia</keyword>
	<keyword>untreated childhood acute lymphoblastic leukemia</keyword>
	<keyword>adult acute lymphoblastic leukemia remission</keyword>
	<keyword>childhood acute lymphoblastic leukemia remission</keyword>
	<keyword>untreated hairy cell leukemia</keyword>
	<keyword>progressive hairy cell leukemia , initial treatment</keyword>
	<keyword>refractory hairy cell leukemia</keyword>
	<keyword>stage II childhood Hodgkin lymphoma</keyword>
	<keyword>stage I childhood Hodgkin lymphoma</keyword>
	<keyword>stage III childhood Hodgkin lymphoma</keyword>
	<keyword>stage IV childhood Hodgkin lymphoma</keyword>
	<keyword>recurrent/refractory childhood Hodgkin lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
	<keyword>stage I adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage II adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage III adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage IV adult T-cell leukemia/lymphoma</keyword>
	<keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage I mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage II mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage III mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage IV mycosis fungoides/Sezary syndrome</keyword>
	<keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
	<keyword>noncontiguous stage II small lymphocytic lymphoma</keyword>
	<keyword>noncontiguous stage II marginal zone lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>stage I marginal zone lymphoma</keyword>
	<keyword>stage I small lymphocytic lymphoma</keyword>
	<keyword>stage II small lymphocytic lymphoma</keyword>
	<keyword>stage II marginal zone lymphoma</keyword>
	<keyword>stage III small lymphocytic lymphoma</keyword>
	<keyword>stage III marginal zone lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>contiguous stage II marginal zone lymphoma</keyword>
	<keyword>contiguous stage II small lymphocytic lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
</DOC>